Cargando…

Which Bisphosphonate? It's the Compliance!: Decision Analysis

BACKGROUND: The best options of several bisphosphonates for prevention of osteoporotic fractures in postmenopausal women remain controversial. We determined which bisphosphonate provides better efficacy in prevention of osteoporotic fractures using a decision analysis tool, in terms of quality of li...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, You Jin, Park, Chan Ho, Lee, Young-Kyun, Ha, Yong-Chan, Koo, Kyung-Hoi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society for Bone and Mineral Research 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900963/
https://www.ncbi.nlm.nih.gov/pubmed/27294079
http://dx.doi.org/10.11005/jbm.2016.23.2.79
_version_ 1782436713706029056
author Lee, You Jin
Park, Chan Ho
Lee, Young-Kyun
Ha, Yong-Chan
Koo, Kyung-Hoi
author_facet Lee, You Jin
Park, Chan Ho
Lee, Young-Kyun
Ha, Yong-Chan
Koo, Kyung-Hoi
author_sort Lee, You Jin
collection PubMed
description BACKGROUND: The best options of several bisphosphonates for prevention of osteoporotic fractures in postmenopausal women remain controversial. We determined which bisphosphonate provides better efficacy in prevention of osteoporotic fractures using a decision analysis tool, in terms of quality of life. METHODS: A decision analysis model was constructed containing final outcome score and the probability of vertebral and hip fracture within 1 year. Final outcome was defined as health-related quality of life, and was used as an utility in the decision tree. Probabilities were obtained by literature review, and health-related quality of life was evaluated by consensus committee. A roll back tool was used to determine the best bisphosphonate, and sensitivity analysis was performed to compensate for decision model uncertainty. RESULTS: The decision model favored bisphosphonate with higher compliance in terms of quality of life. In one-way sensitivity analysis, ibandronate was more beneficial than the others, when probability of compliance on ibandronate was above 0.589. CONCLUSIONS: In terms of quality of life, the decision analysis model showed that compliance was most important for patients in real world, regardless of type of bisphosphonate.
format Online
Article
Text
id pubmed-4900963
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher The Korean Society for Bone and Mineral Research
record_format MEDLINE/PubMed
spelling pubmed-49009632016-06-10 Which Bisphosphonate? It's the Compliance!: Decision Analysis Lee, You Jin Park, Chan Ho Lee, Young-Kyun Ha, Yong-Chan Koo, Kyung-Hoi J Bone Metab Original Article BACKGROUND: The best options of several bisphosphonates for prevention of osteoporotic fractures in postmenopausal women remain controversial. We determined which bisphosphonate provides better efficacy in prevention of osteoporotic fractures using a decision analysis tool, in terms of quality of life. METHODS: A decision analysis model was constructed containing final outcome score and the probability of vertebral and hip fracture within 1 year. Final outcome was defined as health-related quality of life, and was used as an utility in the decision tree. Probabilities were obtained by literature review, and health-related quality of life was evaluated by consensus committee. A roll back tool was used to determine the best bisphosphonate, and sensitivity analysis was performed to compensate for decision model uncertainty. RESULTS: The decision model favored bisphosphonate with higher compliance in terms of quality of life. In one-way sensitivity analysis, ibandronate was more beneficial than the others, when probability of compliance on ibandronate was above 0.589. CONCLUSIONS: In terms of quality of life, the decision analysis model showed that compliance was most important for patients in real world, regardless of type of bisphosphonate. The Korean Society for Bone and Mineral Research 2016-05 2016-05-31 /pmc/articles/PMC4900963/ /pubmed/27294079 http://dx.doi.org/10.11005/jbm.2016.23.2.79 Text en Copyright © 2016 The Korean Society for Bone and Mineral Research http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Lee, You Jin
Park, Chan Ho
Lee, Young-Kyun
Ha, Yong-Chan
Koo, Kyung-Hoi
Which Bisphosphonate? It's the Compliance!: Decision Analysis
title Which Bisphosphonate? It's the Compliance!: Decision Analysis
title_full Which Bisphosphonate? It's the Compliance!: Decision Analysis
title_fullStr Which Bisphosphonate? It's the Compliance!: Decision Analysis
title_full_unstemmed Which Bisphosphonate? It's the Compliance!: Decision Analysis
title_short Which Bisphosphonate? It's the Compliance!: Decision Analysis
title_sort which bisphosphonate? it's the compliance!: decision analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900963/
https://www.ncbi.nlm.nih.gov/pubmed/27294079
http://dx.doi.org/10.11005/jbm.2016.23.2.79
work_keys_str_mv AT leeyoujin whichbisphosphonateitsthecompliancedecisionanalysis
AT parkchanho whichbisphosphonateitsthecompliancedecisionanalysis
AT leeyoungkyun whichbisphosphonateitsthecompliancedecisionanalysis
AT hayongchan whichbisphosphonateitsthecompliancedecisionanalysis
AT kookyunghoi whichbisphosphonateitsthecompliancedecisionanalysis